Marina Biotech this week presented early results from in vivo studies in rodent cancer models demonstrating effective delivery of a microRNA mimetic using the company's di-alkylated amino acid, or DiLA2, delivery system.
Marina Provides Initial Data on miRNA Mimetic Knockdown, Touts Breadth of Growing Delivery Portfolio
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.